Not all care gaps are equal under value-based care contracts. A missed diabetic eye exam and a missed HbA1c draw both count as HEDIS gaps. But one of them — the HbA1c — has a direct pathway to an avoidable ER visit and a 30-day readmission that will show up in your quality scorecard and your cost reconciliation simultaneously. Understanding which chronic disease engagement failures carry the heaviest financial penalty exposure is the first step toward prioritizing your outreach resources correctly.
This isn't a theoretical exercise. For health systems and ACO participants managing attributed populations under MSSP, Medicare Advantage, or commercial VBC agreements, the financial architecture of those contracts maps quality performance directly to shared savings or shared risk. Getting the prioritization wrong — spending coordinator time on low-risk HEDIS gaps while high-risk engagement failures accumulate — is a financial decision whether it's recognized as one or not.
How VBC Penalty Structures Actually Work
The penalty mechanism varies by contract type, but the underlying logic is consistent: if your attributed population's quality metrics fall below the thresholds specified in your VBC agreement, either shared savings are reduced, shared risk payments are triggered, or quality bonus payments don't materialize. In MSSP Track 1 (upside only), the impact is foregone savings. In MSSP Enhanced and most commercial two-sided arrangements, the impact is an actual financial penalty — real money out of the health system's budget.
The measures that trigger penalties most often in chronic disease populations cluster into three categories:
- Process measures tied to preventable acute events: Medication adherence for chronic conditions (MA plans measure PDC on statins, ACE inhibitors/ARBs, and diabetes medications), 30-day all-cause readmission rates, and ED utilization for ambulatory-care-sensitive conditions.
- HEDIS outcome measures for major chronic conditions: Comprehensive Diabetes Care (CDC) composite, Controlling High Blood Pressure (CBP), and COPD/asthma medication management measures.
- Transition of care measures: Timely follow-up after ED visits and hospital discharges, medication reconciliation post-discharge, and care plan completion rates.
What's important to understand is that these categories don't operate independently. A CHF patient who isn't adherent to their ACE inhibitor and loop diuretic is simultaneously at risk for a readmission (category 1), likely to have an uncontrolled blood pressure that affects CBP measures (category 2), and statistically more likely to fail a timely follow-up if they're already disengaged from the care system (category 3). The financial exposure compounds across categories from a single engagement failure.
The Measures With the Largest Penalty Surface
HbA1c Control in Diabetic Populations
The Comprehensive Diabetes Care (CDC) HEDIS measure includes HbA1c testing, HbA1c control (<8%), and a set of associated process measures (nephropathy screening, retinal exam, BP control). For a health system with 2,000 attributed diabetic lives, the CDC composite weight in quality scoring is substantial. The HbA1c control threshold — percentage of patients with HbA1c below 8.0% — is one of the most frequently missed sub-measures, and it's almost entirely driven by medication adherence and clinical follow-up.
The engagement failure that most often precedes an HbA1c measurement miss isn't a single no-show. It's a sequence: the patient's metformin PDC drops below 0.75 in the spring, they miss a medication management visit in the summer, and by Q3 when the measurement window matters most for year-end HEDIS reporting, their HbA1c has drifted to 8.8% and the clinical team finds out at an October visit that's too late to meaningfully improve the measure for the reporting year.
Blood Pressure Control in Hypertensive Patients
Controlling High Blood Pressure (CBP) measures the percentage of hypertensive patients with BP below 140/90. For MSSP and many MA plans, CBP has significant weight in quality scoring. The challenge for care teams is that BP control is highly dependent on medication adherence to antihypertensives — particularly for patients on multi-drug regimens — and antihypertensive PDC is a measure that directly affects quality bonus payments under most current MA contracts.
A hypertensive patient who goes 90 days without a BP reading (no in-office visit, no home monitoring submission) creates two problems: the care team has no current clinical picture, and the measure is effectively an uncontrolled gap in the HEDIS dataset. The HEDIS CBP measure requires a documented BP reading within the measurement year — if none exists, the patient counts as non-compliant regardless of their actual clinical status.
30-Day Readmission Rates and the MSSP Cost Efficiency Link
Under MSSP, quality measures affect the savings sharing percentage — but the per-beneficiary-per-year (PBPM) cost of your attributed population is what determines whether savings exist to share in the first place. A 30-day readmission for a CHF patient costs roughly $15,000 to $25,000 in additional acute care spend depending on severity and length of stay. That single event can meaningfully shift a small ACO's PBPM calculation for a performance period.
The predictability point here is specific: most CHF readmissions within 30 days are preceded by identifiable engagement failures in the prior two to three weeks — missed furosemide or spironolactone refills, missed follow-up appointments, and absence of weight monitoring data. These aren't unpredictable clinical events; they're the endpoint of a pattern that was visible in the data if anyone was watching for it.
What Makes Chronic Disease Engagement Gaps Predictable
The financial case for proactive engagement is straightforward. What's less obvious is which specific engagement signals are most predictive of the penalty-generating events described above. From a clinical informatics perspective, the signals that most reliably precede a costly quality failure are:
- PDC drop below 0.80 on a primary maintenance medication: For metformin in Type 2 diabetes, ACE inhibitors or ARBs in CHF, and loop diuretics in fluid-overload management, a PDC drop below 0.80 in the preceding 90 days is among the strongest leading indicators of an impending clinical deterioration or HEDIS measure miss.
- Post-discharge outreach non-response within 72 hours: Patients who don't respond to any post-discharge outreach within 72 hours are significantly more likely to miss the 7-day and 14-day follow-up appointments — which are both clinical risks and quality measure components under transition of care measures.
- Diagnostic test overdue by 45 days or more: When an HbA1c draw or annual BMP is overdue by more than 45 days and no pending order exists in the EHR, that's typically a signal of care plan disengagement, not just scheduling delay.
These signals are available from data sources most health systems already have: PBM claims feeds, EHR scheduling data, and ADT feeds from the hospital. The gap is usually not in the data availability — it's in whether anyone is querying these signals against a current patient panel on a rolling basis and acting on them before the window closes.
The Quality-Cost Feedback Loop
Here's the financial dynamic that VBC operations leaders should understand clearly: quality penalties and excess cost accumulate from the same population segment. The patients who generate readmissions and ED visits are often the same patients who are missing HEDIS measures. Addressing chronic disease engagement gaps isn't a quality improvement initiative that trades off against cost management — it's both simultaneously.
In our work with early-stage health system implementations, we've found that the highest-value use of outreach resources is targeting the patients who sit at the intersection of low medication PDC, recent care plan disengagement, and a pending quality measure window — not the patients who show up first on a general high-risk score. The general high-risk score tells you who has the most complex clinical picture. The engagement signal tells you who is actively losing the thread on managing that complexity right now.
The Timing Problem in VBC Reporting
One underappreciated aspect of HEDIS-based VBC penalty structures is that the measurement year is fixed. Most HEDIS measures are assessed on a January to December calendar year, with final rates submitted in the spring of the following year. A patient who misses their HbA1c draw in November and has it completed in February of the next year doesn't help your current year's CDC composite — the measure window has closed.
This creates a seasonal urgency pattern for care teams: the Q3 and early Q4 window is critical for closing outstanding HEDIS gaps before the measurement year ends. Organizations that don't have a mechanism to flag which patients have open gaps and are at risk of the window closing are operating blind in the most consequential part of the reporting year.
We're not saying that care gap closure is purely a financial exercise. The clinical and financial priorities genuinely align here — the patients most at risk of missing HEDIS measures are typically the same patients who are at elevated clinical risk. But understanding the financial architecture of your VBC contracts, and mapping it to specific engagement failure patterns, is how care teams make prioritization decisions that are defensible both clinically and operationally.
Translating This Into Outreach Prioritization
The practical output of this analysis for a care management team is a tiered outreach priority framework:
- Tier 1 (immediate, coordinator-level outreach): Post-discharge patients with no confirmed follow-up, and CHF/COPD patients with medication PDC below 0.70 on primary maintenance drugs. Financial exposure is highest, and the intervention window is shortest.
- Tier 2 (automated outreach with escalation logic): Diabetic patients with HbA1c overdue by more than 90 days, hypertensive patients with no BP reading in 60 days, patients approaching a Q3 HEDIS measure window with an open gap. These benefit from early automated outreach that escalates to coordinator if unresponsive.
- Tier 3 (batch outreach, lower urgency): Patients with a single open HEDIS process measure (annual retinal exam, nephropathy screen) where the clinical timeline is less urgent and the financial penalty exposure is limited to quality score impact rather than acute cost impact.
Running this framework requires a care management system that can pull engagement signals in near-real-time and map them against the current performance period's penalty structure. That infrastructure is the investment that makes the financial case for proactive engagement concrete — not because it changes the clinical logic, but because it makes the intervention timing specific enough to act on before the penalty window closes.
